Studies of bempedoic acid in people
8 studies gave bempedoic acid to people and measured what changed
| What changed | Design | People | Source |
|---|---|---|---|
down: Lowers the risk of major adverse limb events36% down: Decreases total major adverse limb events2.9 with bempedoic acid versus 4.0 with placebo down: Lowers the risk of major adverse cardiovascular events or major adverse limb eventsHR, 0.87 [95% CI, 0.80–0.95] | Randomized trialmedian of 40.6 months | 13,970 peopleBoth18 to 85 years of agePatients 18 to 85 years of age with history of or at high risk of cardiovascular diseases who were not able to take recommended statin treatment because of intolerance | Circulation, Aug 18, 2026 |
down: Decreases LDL-C−22.75% up: Increases uric acid+0.96 mg/dL | Treated cohortmedian follow-up duration of 28 weeks (IQR 23–47 weeks) | 125 people79.2% were malemean age 62.4 ± 10.1 yearsPatients with CCS, aged ≥18 years, with LDL-C levels ≥ 55 mg/dL despite at least 8 weeks of stable intensive lipid-lowering therapy | Journal of clinical medicine, Aug 5, 2026 |
down: Decreases LDL cholesterol-18.02% (95% CI, -18.83 to -17.21) | Review of trials | 6,025 people pooledOn top of statin therapy | Journal of clinical lipidology, Feb 26, 2026 |
| Randomized trialmedian follow-up 40.6 months | 13,970 people66 ±9 yearsOlder adults; in patients with elevated steatosis scores | European journal of preventive cardiology, Feb 16, 2026 | |
down: Decreases LDL-C-19% (IQR -36.4% to -3.6%, p < 0.01) down: Decreases C-reactive protein-34.0% (p < 0.01) | Trial12 weeks | 180 peoplePatient cohorts | medRxiv, Feb 9, 2026 |
down: Decreases LDL-C-24.3% (95% CI -27.8 to -20.9) down: Lowers the risk of major adverse cardiovascular eventsRR 0.81 (95% CI 0.68–0.96) no change: Has no effect on mortalityRR 0.87 (95% CI 0.53–1.43) | Review of trials | 22,345 people pooledHypercholesterolemia | AHA Scientific Sessions 2025 abstract, Nov 3, 2025 |
down: Decreases non-HDL cholesterolMD -15.50 mg/dL; 95% CI -18.95 to -12.04 | Review of trials12 weeks | 3,034 people pooledBothmean 65.3 ± 9.1 (cases) and 66.2 ± 8.8 (controls)Patient cohorts | AHA Scientific Sessions 2025 abstract, Nov 3, 2025 |
down: Lowers the risk of major adverse cardiovascular events-14% (HR 0.86, 95% CI 0.76-0.97) down: Decreases LDL cholesterol-20.6% (95% CI, -21.7 to -19.6%) | Randomized trial6 months | 8,217 peopleMonotherapy in statin-intolerant patients without baseline lipid lowering therapies | AHA Scientific Sessions 2025 abstract, Nov 3, 2025 |